350 related articles for article (PubMed ID: 31599389)
21. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
22. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
[TBL] [Abstract][Full Text] [Related]
24. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
[TBL] [Abstract][Full Text] [Related]
25. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
[TBL] [Abstract][Full Text] [Related]
26. Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients.
Murate K; Maeda K; Nakamura M; Sugiyama D; Wada H; Yamamura T; Sawada T; Mizutani Y; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Miyahara R; Ishigami M; Nishikawa H; Fujishiro M
Inflamm Bowel Dis; 2020 Oct; 26(11):1669-1681. PubMed ID: 32405651
[TBL] [Abstract][Full Text] [Related]
27. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
28. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
29. Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Pauwels RWM; Ten Bokkel Huinink S; van der Woude CJ; Doukas M; Oudijk L; de Vries AC
Scand J Gastroenterol; 2023; 58(9):980-987. PubMed ID: 36970968
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of innovative immunoassays for serum ustekinumab and anti-ustekinumab antibody levels in Crohn's disease.
Morita Y; Imai T; Bamba S; Takahashi K; Inatomi O; Miyazaki T; Watanabe K; Nakamura S; Yoshida A; Endo Y; Ohmiya N; Tsujikawa T; Andoh A
J Gastroenterol Hepatol; 2020 Jul; 35(7):1163-1170. PubMed ID: 31860733
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C; Nachury M; Bourreille A; Roblin X; Peyrin-Biroulet L; Viennot S; Flamant M; Laharie D; Caron B; Dewitte M; Siproudhis L; Fumery M; Bouguen G
BMC Gastroenterol; 2022 Dec; 22(1):498. PubMed ID: 36457080
[TBL] [Abstract][Full Text] [Related]
32. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
[TBL] [Abstract][Full Text] [Related]
33. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
34. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
[TBL] [Abstract][Full Text] [Related]
35. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.
Pan Y; Ahmed W; Mahtani P; Wong R; Longman R; Jeremy Lukin D; Scherl EJ; Battat R
Inflamm Bowel Dis; 2022 Dec; 28(12):1865-1871. PubMed ID: 35212368
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
37. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.
Cortes X; Borrás-Blasco J; Antequera B; Fernandez-Martinez S; Casterá E; Martin S; Molés JR
J Clin Pharm Ther; 2017 Apr; 42(2):234-236. PubMed ID: 28004853
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
39. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
40. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]